

ADVANCE and MOTIVATE are 2 randomized, double-masked, placebo-controlled, phase 3 trials. Mod-severe CD with previous intolerance or inadequate response to one or more biologics (MOTIVATE) or conventional therapy (ADVANCE) were randomised to:  
 -IV risankizumab single dose of 600mg or 1200mg or placebo at w0,4 and 8

Coprimary endpoints: clinical remission(CDAI or PRO) and endoscopic response w12.

**Results:**

- ADVANCE, CDAI clinical remission was 45% RISA600, 42% RISA1200 and 25% placebo, p<0.0001.
- ADVANCE endoscopic response was 40% RISA600, 32% RISA1200 and 12% placebo, p<0.0001.
- MOTIVATE, CDAI clinical remission 42% RISA 600m 40% RISA1200, 20%placebo, p<0.0001.
- MOTIVATE endoscopic response was 29% RISA600, 34% RISA1200, 11% placebo, p<0.0001.

**Conclusion:**

Risankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active CD.

